Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net income (loss)	$ 501,728	$ (1,144,350)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation expense	104,825	91,190
Amortization of intangible assets	41,823	40,407
Amortization of deferred license costs	10,196	10,196
Amortization of Debt Issuance Costs	8,628
Bad Debt Expense	7,024
Interest income on long-term note receivable	(9,247)	(9,247)
Stock-based compensation	649,090	286,186
Loss on asset disposal	241
Changes in operating assets and liabilities:
Accounts receivable	486,117	(581,299)
Contract assets	(91,479)	(599,441)
Inventories	219,483	(155,935)
Prepaid expenses and other current assets	(128,592)	(679,540)
Right of use asset	109,308	97,846
Accounts payable and accrued expenses	(2,052,971)	2,062,776
Contract liabilities	3,768,133	(641,412)
Due to affiliates	(264,451)	(863,151)
Lease liability	(102,829)	(97,342)
Net cash provided by (used in) operating activities	3,257,027	(2,183,116)
Cash flows from investing activities:
Purchase of property, plant and equipment	(922,865)	(862,090)
Purchase of intangible asset		(42,500)
Proceeds from sale of equipment	760
Repayment of promissory note	(100,000)
Payment on assumed liability of acquired assets		(85,798)
Project Development Costs	(338,885)
Investment in non-marketable securities	(500,000)
Net cash (used in) investing activities	(1,860,990)	(990,388)
Cash flows from financing activities:
Proceeds from received conversion of exercised warrants		703,438
Distribution paid to NCI	(1,274,000)
Net cash (used in) provided by financing activities	(1,274,000)	703,438
Net increase (decrease) in cash and cash equivalents	122,037	(2,470,066)
Cash and cash equivalents - beginning of period	13,024,381	13,010,356
Cash and cash equivalents - end of period	$ 13,146,418	$ 10,540,290